CURE Foundation orders for five Varian TrueBeam stereotactic radiosurgery and radiation therapy systems

NewsGuard 100/100 Score

Varian Medical Systems, Inc. (NYSE: VAR) today announced that CURE Foundation has placed an order for five Varian TrueBeam™ systems for stereotactic radiosurgery and radiation therapy.  

CURE Foundation, which placed the order in September, plans to install the TrueBeam systems in existing and new clinics on the U.S. East Coast during 2011.  

CURE Foundation was established in Springfield, VA in 2007 as a non-profit organization, with a goal to reduce the cost of healthcare and education and to establish cancer centers around the world.  

"We are excited to partner with Varian, the industry's leading provider of hardware and software for radiotherapy and radiosurgery," said Krish Suthanthiran, founder of CURE Foundation.  "We are working to establish a global network of cancer centers that offer patients high quality, affordable care, and Varian has the technology and products to help us achieve this goal."

"Varian is pleased to support CURE Foundation by supplying cutting-edge technologies for offering cancer patients high-precision radiotherapy treatment, along with the company's industry-leading software products for treatment planning," said Jeffrey Marcus, Varian vice-president for worldwide sales.  "We are excited about supporting CURE's goals of making high-quality cancer care more accessible around the world."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel approach uses patient's cells as "trojan horse" to target lung cancer cells